allogen
hematopoiet
stem
cell
transplant
hsct
routin
clinic
procedur
perform
patient
annual
mostli
treat
patient
haematolog
malign
also
primari
immun
metabol
defici
sourc
stem
cell
bone
marrow
bm
umbil
cord
blood
peripher
blood
stem
cell
pbsc
order
prevent
reject
new
graft
reduc
number
malign
cell
patient
condit
transplant
either
myeloabl
contain
high
dose
cytotox
drug
without
whole
bodi
irradi
reduc
intens
condit
ric
stem
cell
product
use
allogen
hsct
contain
hematopoiet
cell
number
addit
leucocyt
granulocyt
monocyt
qualiti
allogen
stem
cell
graft
time
transplant
import
clinic
outcom
recent
shown
poor
graft
viabil
relat
increas
incid
acut
gvhd
transplant
relat
mortal
indic
stem
cell
graft
composit
respect
antigen
specif
import
immun
reconstitut
clinic
outcom
allogen
hsct
associ
number
seriou
complic
transplant
graft
induc
diseas
gvhd
potenti
life
threaten
condit
donor
graft
attack
recipi
tissu
recent
graft
manipul
transplant
util
prevent
gvhd
exampl
deplet
haploident
stem
cell
graft
deplet
express
receptor
tcr
leav
graft
conflict
data
regard
benefit
allogen
hsct
recent
studi
suggest
favour
clinic
outcom
patient
elev
level
transplant
infect
lymphopen
state
stem
cell
transplant
anoth
complic
associ
high
mortal
morbid
common
agent
caus
infect
viru
ebv
cytomegaloviru
cmv
herp
simplex
viru
hsv
viru
vzv
well
fungal
infect
caus
candida
aspergillu
consider
effort
dedic
reduc
risk
cmv
ebv
reactiv
well
prevent
fungal
infect
prophylact
antimicrobi
drug
administ
patient
donor
pair
screen
prevent
pair
cmv
ebv
donor
recipi
combin
earli
microbiolog
diagnost
moreov
adopt
transfer
clone
use
antivir
treatment
show
possibl
protect
function
mean
evalu
prolifer
cytokin
product
stem
cell
product
use
allogen
hsct
donor
cell
product
stimul
infecti
antigen
commonli
involv
transplant
associ
infecti
complic
result
correl
clinic
outcom
moreov
extens
repertoir
transfer
effector
function
hsv
ebv
cmv
vzv
adenoviru
candida
albican
allogen
donor
stem
cell
graft
associ
absenc
infecti
complic
within
protect
effect
associ
graft
transfus
cell
dose
approxim
cell
stem
cell
product
bm
pbsc
healthi
donor
use
allogen
hsct
obtain
stem
cell
laboratori
karolinska
univers
hospit
one
patient
die
day
data
correspond
stem
cell
donor
exclud
studi
except
comparison
donor
serolog
cellular
respons
measur
fascia
hsv
ebv
cmv
vzv
viral
reactiv
cmv
defin
blood
sampl
cmv
copiesml
assess
pcr
evid
cmv
induc
patholog
biopsi
specimen
affect
organ
viral
reactiv
ebv
defin
clinic
symptomat
diseas
coupl
blood
sampl
ebv
copiesml
assess
pcr
evid
patholog
biopsi
specimen
affect
organ
vzv
reactiv
defin
clinic
symptomat
vzv
diseas
posit
vzv
pcr
sampl
affect
bodi
site
reactiv
defin
clinic
symptomat
diseas
posit
pcr
sampl
affect
bodi
site
coronaviru
pneumonia
defin
clinic
symptomat
diseas
accompani
chest
ct
show
typic
infiltr
respiratori
specimen
assess
pcr
oral
candidiasi
defin
clinic
symptomat
diseas
accompani
posit
oral
fungal
cultur
bacteri
septicaemia
defin
blood
clinic
sepsi
patient
donor
inform
display
tabl
region
ethic
board
grant
ethic
approv
studi
mitogen
antigen
titrat
optim
respons
follow
concentr
use
fascia
flow
cytometr
assay
specif
activ
whole
blood
experi
pokewe
mitogen
pwm
ngml
staphylococc
enterotoxin
b
sea
seb
sigma
aldrich
mo
usa
tuberculin
purifi
protein
deriv
ppd
iuml
tetanu
toxin
tt
staten
serum
institut
copenhagen
dk
candida
albican
greer
laboratori
inc
nc
usa
influenza
vaccin
fluarix
varicella
zoster
viru
vaccin
vzv
varilrix
glaxosmithklin
ab
middlesex
uk
dilut
adenoviru
grade
antigen
cell
extract
ebv
hsv
type
antigen
cmv
grade
antigen
microbix
biosystem
inc
mississauga
canada
function
respons
infecti
antigen
assess
clinic
use
flow
cytometri
base
remov
citrat
stem
cell
product
cell
wash
twice
resuspend
fascia
cultur
media
contain
rpmi
gibco
supplement
human
supplement
iuml
penicillin
iuml
streptomycin
gibco
paisley
uk
mm
invitrogen
md
usa
sandoz
nj
usa
stem
cell
product
bm
pb
stimul
tetanu
toxin
pwm
sea
seb
hsv
antigen
candida
left
unstimul
accord
revis
cell
cultur
ml
cultur
media
contain
incub
day
c
humid
cell
supernat
remov
day
store
c
cytokinechemokin
analysi
perform
cell
stain
simultest
mix
bd
bioscienc
ca
usa
background
fascia
cultur
tube
also
stain
beckman
coulter
marseil
franc
tube
incub
min
room
temperatur
rt
dark
follow
erythrocyt
lyse
io
test
lyse
solut
beckman
coulter
wash
cell
pellet
resuspend
pb
blast
number
acquir
second
navio
flow
cytomet
beckman
coulter
ca
usa
stimul
index
si
number
stimul
blast
divid
number
blast
unstimul
tube
calcul
compar
prolif
respons
infecti
antigen
stimul
index
greater
consid
posit
cellular
respons
base
median
respons
healthi
blood
donor
stimul
influenza
vaccin
tt
si
rang
data
shown
lineag
marker
subtyp
donor
stem
cell
product
analys
flow
cytometri
cell
stain
follow
antibodi
bd
bioscienc
blue
beckman
coulter
miltenyi
biotec
dako
acquisit
perform
navio
flow
cytometri
instrument
analys
use
kaluza
softwar
beckman
coulter
cytokin
chemokin
cultur
supernat
unstimul
fascia
tube
tube
stimul
pwm
cmv
ebv
hsv
patient
measur
milliplex
human
kit
contain
monoclon
antibodi
detect
accord
manufactur
instruct
emd
millipor
corpor
usa
sampl
analysi
perform
magpix
instrument
use
xponent
softwar
luminex
tx
usa
measur
elisa
accord
manufactur
instruct
r
system
mn
usa
anova
follow
multipl
comparison
test
use
determin
differ
group
defin
infecti
complic
well
comparison
cell
frequenc
exact
test
use
nomin
variabl
compar
fascia
respons
reactiv
ebv
cmv
final
composit
analysi
perform
posit
respons
hsv
ebv
cmv
vzv
candida
adenoviru
render
point
maximum
point
student
use
statist
calcul
statist
analysi
consid
statist
signific
statist
analysi
graph
pad
prism
version
graphpad
softwar
inc
ca
usa
use
major
donor
match
unrel
donor
rest
consist
match
sibl
median
age
recipi
year
rang
patient
except
one
chronic
granulomat
diseas
cgd
suffer
haematolog
malign
atg
administ
patient
part
condit
regim
stem
cell
dose
mononuclear
cell
rang
bodyweight
median
took
averag
day
rang
day
engraft
defin
absolut
neutrophil
count
least
occur
clinic
patient
experienc
either
reactiv
one
latent
virus
cmv
hsv
ebv
vzv
suffer
candidiasi
among
seven
case
cmv
recipi
receiv
stem
cell
product
donor
six
recipi
experienc
cmv
infect
two
ebv
recipi
receiv
stem
cell
product
experienc
ebv
reactiv
five
patient
diagnos
gvhd
grade
six
relaps
four
patient
deceas
tabl
sixteen
stem
cell
product
obtain
peripher
blood
five
bm
evalu
cellular
respons
infecti
antigen
prior
transplant
use
modifi
version
fascia
method
cell
left
unstimul
stimul
pwm
seaseb
candida
tt
posit
control
pwm
si
mean
seaseb
si
mean
elicit
posit
prolifer
stem
cell
product
mean
frequenc
cell
product
posit
respons
cmv
vzv
hsv
ebv
tt
candida
influenza
adenoviru
antigen
prolifer
stem
cell
product
analys
show
posit
respons
pwm
posit
ebv
fig
sinc
stem
cell
donor
allogen
hsct
test
humor
respons
serum
igg
hsv
ebv
cmv
vzv
could
compar
prolif
respons
antigen
fascia
method
larg
concurr
serolog
posit
presenc
posit
prolif
respons
antigen
greatest
concord
observ
ebv
donor
show
posit
prolif
respons
ebv
antigen
fascia
method
tabl
next
investig
whether
donor
specif
infecti
agent
could
protect
recipi
stem
cell
transplant
analys
fascia
result
candida
adenoviru
hsv
ebv
cmv
vzv
compar
patient
clinic
record
base
individu
patient
infecti
complic
candida
adenoviru
hsv
ebv
cmv
vzv
tabl
defin
materi
method
section
correspond
fascia
result
divid
two
group
one
group
repres
patient
without
aforement
infecti
complic
ni
n
group
repres
patient
experienc
infecti
complic
n
fascia
data
individu
infecti
agent
compar
ni
group
statist
signific
differ
shown
howev
composit
analysi
group
prolif
respons
fascia
method
test
antigen
clearli
show
strong
correl
ni
statu
presenc
prolif
respons
scp
multipl
antigen
fig
indic
transfer
protect
function
furthermor
nine
patient
experienc
episod
three
patient
tabl
clinic
data
compar
correspond
fascia
respons
cmv
ebv
stimul
patient
reactiv
cmv
infect
posit
fascia
respons
cmv
nine
stem
cell
product
patient
experi
viral
reactiv
within
year
show
posit
respons
cmv
fisher
exact
test
three
patient
two
donor
product
posit
ebv
fascia
one
neg
show
posit
respons
tabl
addit
hematopoiet
stem
cell
donor
stem
cell
product
contain
leucocyt
cellular
content
stem
cell
product
assess
flow
cytometri
analys
use
forward
side
scatter
properti
antibodi
sever
lineag
marker
two
patient
group
infect
infect
ni
compar
evalu
whether
leucocyt
composit
stem
cell
product
differenti
statu
associ
infecti
complic
frequenc
granulocyt
monocyt
lymphocyt
stem
cell
product
similar
group
fig
similarli
analys
differenti
lineag
subset
differ
frequenc
detect
group
fig
c
investig
cytokinechemokin
effector
function
respons
variou
viral
antigen
cell
fascia
cultur
mainli
secret
monocyt
macrophag
innat
immun
system
secret
differ
subset
repres
import
effector
function
adopt
immun
respons
infecti
pathogen
fascia
cultur
supernat
unstimul
cell
cell
stimul
pwm
cmv
ebv
hsv
stem
cell
product
harvest
day
incub
analys
use
multiplex
kit
elisa
result
divid
accord
patient
infecti
complic
yield
two
group
patient
infecti
complic
patient
without
infect
ni
differ
group
concentr
supernat
cultur
stimul
ebv
cmv
hsv
furthermor
concentr
low
differ
background
stimul
posit
control
pwm
shown
compar
unstimul
fascia
cultur
pwm
stimul
increas
secret
fascia
product
differ
secret
ni
group
howev
fascia
supernat
ni
group
stimul
pwm
mean
ngml
contain
significantli
compar
supernat
group
mean
ngml
differ
group
secret
upon
stimul
ebv
cmv
hsv
concentr
differ
group
cultur
stimul
ebv
moreov
cmv
cell
cultur
supernat
concentr
significantli
higher
respect
scp
ni
group
mean
ngml
cmv
ngml
hsv
compar
supernat
infect
group
mean
ngml
cmv
pgml
hsv
similar
signific
trend
seen
product
mean
group
ngml
wherea
mean
concentr
ngml
infect
group
fig
infecti
complic
due
poor
reconstitut
lymphocytopenia
gener
major
caus
morbid
mortal
allogen
hsct
evalu
whether
allogen
stem
cell
graft
abl
reduc
infecti
complic
year
transplant
cell
stem
cell
product
obtain
donor
allogen
hsct
stimul
antigen
associ
infecti
complic
cmv
ebv
hsv
vzv
candida
adenoviru
function
evalu
mean
prolifer
flow
cytometri
base
assay
well
cytokin
product
stem
cell
product
prolifer
posit
control
indic
graft
function
viabl
pretranspl
frequenc
cell
product
posit
respons
infecti
antigen
vari
show
posit
respons
cmv
hsv
vzv
stem
cell
product
posit
ebv
take
donor
age
consider
data
reflect
seropreval
sweden
sinc
moreov
measur
fascia
respons
cmv
ebv
hsv
vzv
concurr
donor
serolog
pathogen
prolif
respons
toward
detect
vast
major
ebv
donor
tabl
agreement
previou
studi
show
ebv
specif
make
circul
ebv
individu
smaller
fraction
cmv
hsv
vzv
donor
show
detect
prolif
respons
like
reflect
greater
variabl
circul
pathogen
furthermor
among
nine
patient
time
clinic
posit
respons
measur
fascia
cmv
correspond
stem
cell
product
tabl
data
show
impend
role
pretranspl
graft
prolifer
assay
provid
addit
inform
regard
donor
cell
immunolog
compet
six
seven
cmv
patient
receiv
stem
cell
cmv
donor
experienc
viral
reactiv
within
line
previou
data
show
cmv
seroposit
independ
risk
factor
cmv
reactiv
patient
clinic
record
assess
infecti
complic
patient
correspond
donor
cell
divid
two
group
one
group
consist
stem
cell
product
transplant
patient
infecti
complic
transplant
patient
without
infecti
complic
ni
respons
cmv
ebv
hsv
vzv
candida
adenoviru
analys
composit
compar
two
group
group
associ
infecti
complic
prolifer
wider
rang
compar
given
patient
experienc
infecti
complic
differ
concentr
two
patient
group
suggest
neither
regulatori
cell
involv
protect
effect
seen
patient
without
infect
howev
product
upon
stimul
cmv
hsv
higher
group
without
infecti
complic
ni
compar
group
infecti
complic
indic
ni
donor
product
contain
pronounc
abil
recogn
execut
effector
function
test
pathogen
compar
group
master
cytokin
cytokin
famili
import
autophagi
host
defenc
pathogen
also
shown
involv
pathogenesi
diseas
bind
receptor
result
transcript
gene
secret
cytokin
famili
member
cytokin
famili
induc
secret
helper
cell
moreov
recent
shown
cell
induc
optim
secret
autocrin
activ
respect
data
propos
also
master
regul
activ
prolifer
protect
allogen
transplant
set
addit
allogen
stimul
per
se
shown
benefici
vitro
studi
demonstr
stimul
viral
antigen
bind
specif
combin
allogen
stimul
increas
number
effector
function
complic
hsct
multifactori
age
malign
treatment
condit
gvhd
deplet
strategi
affect
reconstitut
patient
abil
fight
infect
phenotyp
analysi
donor
stem
cell
product
flow
cytometri
show
differ
frequenc
granulocyt
monocyt
lymphocyt
cell
express
two
group
without
infecti
complic
present
fig
absolut
mononuclear
cell
dose
administ
transplant
differ
group
tabl
yet
increas
overal
surviv
associ
higher
dose
transfer
stem
cell
product
allogen
hsct
author
evalu
clonal
divers
stem
cell
product
light
result
present
perhap
improv
clinic
outcom
due
dose
per
se
rather
effect
cell
composit
regard
seem
donor
graft
wider
repertoir
common
infecti
complic
pronounc
cytokin
product
protect
patient
within
possibl
longer
clone
specif
tetanu
toxin
shown
persist
recipi
year
bone
marrow
transplant
stem
cell
product
studi
manipul
prior
transplant
howev
vast
major
recipi
receiv
cell
deriv
peripher
blood
given
antithymocyt
atg
risk
factor
infect
patient
receiv
atg
seven
belong
group
without
infecti
complic
eight
group
infecti
complic
indic
atg
administr
determin
frequenc
patient
suffer
test
infecti
complic
studi
indic
monitor
function
pathogen
involv
transplant
relat
infecti
complic
import
prior
allogen
hsct
routin
assay
function
allogen
donor
graft
certain
virus
fungi
caus
ill
hsct
could
assist
gaug
individu
risk
infecti
complic
aid
regard
prophylact
therapi
